<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZOLPIDEM TARTRATE - zolpidem tartrate tablet </strong><br>STAT Rx USA LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS<br>Zolpidem tartrate tablets, USP -CIV<br>Initial U.S. Approval: 1992</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage (<a href="#ID4">1</a>)                                                                                                                                                03/2007 </p>
<p class="Highlighta"><span class="Bold">Warnings and Precautions</span> </p>
<p class="Highlighta">                 Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (<a href="#ID35">5.2</a>)                                                                           03/2007 </p>
<p class="Highlighta">                <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavioral changes (<a href="#ID37">5.3</a>)                                                                                       03/2007 </p>
<p class="Highlighta">                 Special populations (<a href="#ID43">5.6</a>)                                                                                                                                03/2007 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Zolpidem tartrate tablets, USP are indicated for the short-term treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulties with sleep initiation. Zolpidem tartrate tablets, USP have been shown to decrease sleep latency for up to 35 days in controlled clinical studies. (<a href="#ID4">1</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Adult dose: 10 mg once daily immediately before bedtime (<a href="#ID12">2.1</a>)</li>
<li> Elderly/debilitated patients/hepatically impaired: 5 mg once daily immediately before bedtime (<a href="#ID14">2.2</a>)</li>
<li> Downward dosage adjustment may be necessary when used with CNS depressants (<a href="#ID16">2.3</a>)</li>
<li> Should not be taken with or immediately after a meal (<a href="#ID18">2.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">5 mg and 10 mg tablets. Tablets not scored. (<a href="#ID22">3</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolpidem tartrate or to any of the inactive ingredients in the formulation (<a href="#ID28">4.1</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Need to evaluate for co-morbid diagnosis: Reevaluate if <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> persists after 7 to 10 days of use (<a href="#ID33">5.1</a>)</li>
<li>Severe anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported. Do not rechallenge if such reactions occur. (<a href="#ID35">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span>, behavioral changes and complex behaviors: May include "sleep-driving" and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Immediately evaluate any new onset behavioral changes. (<a href="#ID37">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>: Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or, suicidal thinking may occur. Prescribe the least amount feasible to avoid <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdose</span> (<a href="#ID37">5.3</a>,<a href="#ID43">5.6</a>)</li>
<li>Withdrawal effects: Symptoms may occur with rapid dose reduction or discontinuation (<a href="#ID39">5.4</a>, <a href="#ID90">9.3</a>)</li>
<li>CNS depressant effects: Use can impair alertness and motor coordination. If used in combination with other CNS depressants, dose reductions may be needed due to additive effects. Do not use with alcohol (<a href="#ID16">2.3</a>, <a href="#ID41">5.5</a>)</li>
<li>Elderly/debilitated patients: Use lower dose due to impaired motor, cognitive performance and increased sensitivity (<a href="#ID14">2.2</a>, <a href="#ID43">5.6</a>)</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, mild to moderate <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, impaired drug metabolism or hemodynamic responses, mild to moderate <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>: Use with caution and monitor closely. (<a href="#ID43">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most commonly observed adverse reactions were: </p>
<p class="Highlighta">Short-term (&lt; 10 nights): <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </p>
<p class="Highlighta">Long-term (28 - 35 nights): <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and drugged feelings (<a href="#ID51">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-269-544-2299 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>CNS depressants: Enhanced CNS-depressant effects with combination use. Use with alcohol causes additive psychomotor impairment (<a href="#ID60">7.1</a>)</li>
<li>Imipramine: Decreased alertness observed with combination use. (<a href="#ID60">7.1</a>)</li>
<li>Chlorpromazine:Impaired alertness and psychomotor performance observed with combination use (<a href="#ID60">7.1</a>)</li>
<li>Rifampin: Combination use decreases exposure to and effects of zolpidem (<a href="#ID62">7.2</a>)</li>
<li>Ketoconazole: Combination use increases exposure to and effect of zolpidem (<a href="#ID62">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Based on animal data, zolpidem may cause fetal harm. (<a href="#ID71">8.1</a>)</li>
<li>Nursing mothers: Zolpidem is excreted in human milk. (<a href="#ID75">8.3</a>)</li>
<li>Pediatric use: Safety and effectiveness not established. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> (incidence rate 7.4%) and other psychiatric and/or nervous system adverse reactions were observed frequently in a study of pediatric patients with Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<a href="#ID43">5.6</a>, <a href="#ID77">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.2" class="toc">2.1 Dosage in adults</a></h2>
<h2><a href="#section-2.3" class="toc">2.2 Special populations</a></h2>
<h2><a href="#section-2.4" class="toc">2.3 Use with CNS depressants</a></h2>
<h2><a href="#section-2.5" class="toc">2.4 Administration</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Need to evaluate for co-morbid diagnoses</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavioral changes</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Withdrawal effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 CNS depressant effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Special populations</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.2" class="toc">6.1 Clinical trials experience</a></h2>
<h1><a href="#section-7" class="toc">7. Drug Interactions:</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CNS active drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs that affect drug metabolism via cytochrome P450</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Other drugs with no interaction with zolpidem</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drug-laboratory tests interactions</a></h2>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric use</a></h2>
<h1><a href="#section-9" class="toc">9. DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10. OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Signs and symptoms</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Recommended treatment</a></h2>
<h1><a href="#section-11" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13. NONCLINICAL  TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, mutagenesis, impairment of fertility</a></h2>
<h1><a href="#section-14" class="toc">14. CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Transient insomnia</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Chronic insomnia</span></a></h2>
<h2><a href="#section-14.3" class="toc">14.3 Studies pertinent to safety concerns for sedative/hypnotic drugs</a></h2>
<h1><a href="#section-15" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Severe <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Sleep-driving and other complex behaviors</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Administration instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID4"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID5"></a><a name="section-1.1"></a><p></p>
<p class="First">Zolpidem tartrate tablets, USP are indicated for the short-term treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulties with sleep initiation. Zolpidem tartrate tablets, USP have been shown to decrease sleep latency for up to 35 days in controlled clinical studies <span class="Italics">[see <a href="#ID109">Clinical Studies (14)</a>].</span></p>
<p>The clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID9"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID10"></a><a name="section-2.1"></a><p></p>
<p class="First">The dose of zolpidem tartrate tablets should be individualized.</p>
</div>
<div class="Section">
<a name="ID12"></a><a name="section-2.2"></a><p></p>
<h2>2.1 Dosage in adults</h2>
<p class="First">The recommended dose for adults is 10 mg once daily immediately before bedtime. The total zolpidem tartrate dose should not exceed 10 mg per day.</p>
</div>
<div class="Section">
<a name="ID14"></a><a name="section-2.3"></a><p></p>
<h2>2.2 Special populations</h2>
<p class="First">Elderly or debilitated patients may be especially sensitive to the effects of zolpidem tartrate. Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> do not clear the drug as rapidly as normal subjects. The recommended dose of zolpidem tartrate in both of these patient populations is 5 mg once daily immediately before bedtime <span class="Italics">[see <a href="#ID43">Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section">
<a name="ID16"></a><a name="section-2.4"></a><p></p>
<h2>2.3 Use with CNS depressants</h2>
<p class="First">Dosage adjustment may be necessary when zolpidem tartrate tablets are combined with other CNS depressant drugs because of the potentially additive effects <span class="Italics">[see <a href="#ID41">Warnings and Precautions (5.5)</a>].</span></p>
</div>
<div class="Section">
<a name="ID18"></a><a name="section-2.5"></a><p></p>
<h2>2.4 Administration</h2>
<p class="First">The effect of zolpidem tartrate tablets may be slowed by ingestion with or immediately after a meal.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID22"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID23"></a><a name="section-3.1"></a><p></p>
<p class="First">Zolpidem tartrate tablets are available in 5 mg and 10 mg strength tablets for oral administration. Tablets are <span class="Underline">not</span> scored.</p>
<p>Zolpidem tartrate 5 mg tablets are red colored, capsule shaped tablets with the Torrent logo debossed on one side and ‘5 MG’ debossed on the other side.</p>
<p>Zolpidem tartrate 10 mg tablets are peach-yellow colored, capsule shaped tablets with the Torrent logo debossed on one side and ‘10 MG’ debossed on the other side.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID27"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID28"></a><a name="section-4.1"></a><p></p>
<p class="First">Zolpidem tartrate tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolpidem tartrate or to any of the inactive ingredients in the formulation. Observed reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> <span class="Italics">[see <a href="#ID35">Warnings and Precautions (5.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID32"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS</h1>
<div class="Section">
<a name="ID33"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Need to evaluate for co-morbid diagnoses</h2>
<p class="First">Because <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> should be initiated only after a careful evaluation of the patient. <span class="Bold">The failure of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. </span>Worsening of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including zolpidem.</p>
</div>
<div class="Section">
<a name="ID35"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span></h2>
<p class="First">Rare cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including zolpidem. Some patients have had additional symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, throat closing or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that suggest <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Some patients have required medical therapy in the emergency department. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involves the throat, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> after treatment with zolpidem should not be rechallenged with the drug.</p>
</div>
<div class="Section">
<a name="ID37"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavioral changes</h2>
<p class="First">A variety of <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> and behavior changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (e.g., <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span> and extroversion that seemed out of character), similar to effects produced by alcohol and other CNS depressants. Visual and <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">auditory hallucinations</span> have been reported as well as behavioral changes such as <span class="product-label-link" type="condition" conceptid="4092397" conceptname="Bizarre behavior">bizarre behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>. In controlled trials, &lt;1% of adults with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> who received zolpidem reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. In a clinical trial, 7.4% of pediatric patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> associated with attention-deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>), who received zolpidem reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> <span class="Italics">[see <a href="#ID77">Use in Specific Populations (8.4)</a>].</span></p>
<p>Complex behaviors such as "sleep-driving" (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> for the event) have been reported with sedative-hypnotics, including zolpidem. These events can occur in sedative-hypnotic-naive as well as in sedative-hypnotic-experienced persons. Although behaviors such as "sleep-driving" may occur with zolpidem tartrate tablets alone at therapeutic doses, the use of alcohol and other CNS depressants with zolpidem tartrate tablets appears to increase the risk of such behaviors, as does the use of zolpidem tartrate tablets at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of zolpidem tartrate tablets should be strongly considered for patients who report a "sleep-driving" episode. Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with "sleep-driving", patients usually do not remember these events. <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and other neuro-<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> may occur unpredictably.</p>
<p>In primarily depressed patients, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, including suicidal thoughts and actions (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>), has been reported in association with the use of sedative/hypnotics.</p>
<p>It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.</p>
</div>
<div class="Section">
<a name="ID39"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Withdrawal effects</h2>
<p class="First">Following the rapid dose decrease or abrupt discontinuation of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs <span class="Italics">[see <a href="#ID85">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9)</a>].</span></p>
</div>
<div class="Section">
<a name="ID41"></a><a name="section-5.5"></a><p></p>
<h2>5.5 CNS depressant effects</h2>
<p class="First">Zolpidem tartrate tablets, like other sedative/hypnotic drugs, have CNS-depressant effects. <span class="Underline">Due to the rapid onset of action, zolpidem tartrate tablets should only be taken immediately prior to going to bed. </span>Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of zolpidem tartrate tablets. Zolpidem tartrate tablets showed additive effects when combined with alcohol and should not be taken with alcohol. Patients should also be cautioned about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when zolpidem tartrate tablets are administered with such agents because of the potentially additive effects. </p>
</div>
<div class="Section">
<a name="ID43"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Special populations</h2>
<p class="First"><span class="Italics">Use in the elderly and/or debilitated patients: </span>Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended zolpidem tartrate tablets dosage is 5 mg in such patients to decrease the possibility of side effects <span class="Italics">[see <a href="#ID12">Dosage and Administration (2.2)</a>]. </span>These patients should be closely monitored.</p>
<p><span class="Italics">Use in patients with concomitant illness: </span>Clinical experience with zolpidem tartrate tablets in patients with concomitant systemic illness is limited. Caution is advisable in using zolpidem tartrate tablets in patients with diseases or conditions that could affect metabolism or hemodynamic responses.</p>
<p>Although studies did not reveal respiratory depressant effects at hypnotic doses of zolpidem in normal subjects or in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), a reduction in the Total Arousal Index together with a reduction in lowest oxygen saturation and increase in the times of oxygen desaturation below 80% and 90% was observed in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span> when treated with zolpidem tartrate tablets (10 mg) when compared to placebo. Since sedative/hypnotics have the capacity to depress respiratory drive, precautions should be taken if zolpidem tartrate tablets are prescribed to patients with compromised respiratory function. Post-marketing reports of <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, most of which involved patients with pre-existing respiratory impairment, have been received. Zolpidem tartrate tablets should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea syndrome</span> or <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>Data in end-stage <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> patients repeatedly treated with zolpidem tartrate tablets did not demonstrate drug accumulation or alterations in pharmacokinetic parameters. No dosage adjustment in renally impaired patients is required; however, these patients should be closely monitored <span class="Italics">[see <a href="#ID101">Clinical Pharmacology (12.3)</a>].</span></p>
<p>A study in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> did reveal prolonged elimination in this group; therefore, treatment should be initiated with 5 mg in patients with hepatic compromise, and they should be closely monitored <span class="Italics">[see<a href="#ID12"> Dosage and Administration (2.2)</a> and <a href="#ID101">Clinical Pharmacology (12.3)</a>].</span></p>
<p><span class="Italics">Use in patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>: </span>As with other sedative/hypnotic drugs, zolpidem tartrate tablets should be administered with caution to patients exhibiting signs or symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional over-dosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.</p>
<p><span class="Italics">Use in pediatric patients: </span>Safety and effectiveness of zolpidem have not been established in pediatric patients. In an 8-week study in pediatric patients (aged 6-17 years) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> associated with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>, zolpidem did not decrease sleep latency compared to placebo. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> were reported in 7.4% of the pediatric patients who received zolpidem; none of the pediatric patients who received placebo reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> <span class="Italics">[see <a href="#ID77">Use in Specific Populations (8.4)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID47"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID48"></a><a name="section-6.1"></a><p></p>
<p class="First">The following serious reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li>Serious anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> <span class="Italics">[see <a href="#ID35">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span>, behavior changes, and complex behaviors <span class="Italics">[see <a href="#ID37">Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Withdrawal effects <span class="Italics">[see <a href="#ID39">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>CNS-depressant effects <span class="Italics">[see <a href="#ID41">Warnings and Precautions (5.5)</a>]</span>
</li>
</ul>
</div>
<div class="Section">
<a name="ID51"></a><a name="section-6.2"></a><p></p>
<h2>6.1 Clinical trials experience</h2>
<p class="First"><span class="Italics">Associated with discontinuation of treatment: </span>Approximately 4% of 1,701 patients who received zolpidem at all doses (1.25 to 90 mg) in U.S. premarketing clinical trials discontinued treatment because of an adverse reaction. Reactions most commonly associated with discontinuation from U.S. trials were daytime <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> (0.5%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.4%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.6%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.5%).</p>
<p>Approximately 4% of 1,959 patients who received zolpidem at all doses (1 to 50 mg) in similar foreign trials discontinued treatment because of an adverse reaction. Reactions most commonly associated with discontinuation from these trials were daytime <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> (1.1%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (0.8%), <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> (0.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.4%), and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> (0.4%).</p>
<p>Data from a clinical study in which selective serotonin reuptake inhibitor (SSRI)-treated patients were given zolpidem revealed that four of the seven discontinuations during double-blind treatment with zolpidem (n=95) were associated with impaired concentration, continuing or aggravated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>; one patient treated with placebo (n=97) was discontinued after an <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span>.</p>
<p><span class="Italics">Most commonly observed adverse reactions in controlled trials: </span>During short-term treatment (up to 10 nights) with zolpidem tartrate tablets at doses up to 10 mg, the most commonly observed adverse reactions associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> (reported by 2% of zolpidem patients), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (1%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1%). During longer-term treatment (28 to 35 nights) with zolpidem at doses up to 10 mg, the most commonly observed adverse reactions associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (5%) and drugged feelings (3%).</p>
<p><span class="Italics">Adverse reactions observed at an incidence of  </span>≥<span class="Italics">1% in controlled trials: </span>The following tables enumerate treatment-emergent adverse reactions frequencies that were observed at an incidence equal to 1% or greater among patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> who received zolpidem tartrate and at a greater incidence than placebo in U.S. placebo-controlled trials. Events reported by investigators were classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms for the purpose of establishing event frequencies. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in these clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigators involving related drug products and uses, since each group of drug trials is conducted under a different set of conditions. However, the cited figures provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the population studied. </p>
<p>The following table was derived from results of 11 placebo-controlled short-term U.S. efficacy trials involving zolpidem in doses ranging from 1.25 to 20 mg. The table is limited to data from doses up to and including 10 mg, the highest dose recommended for use.</p>
<a name="ID53"></a><table width="99%">
<caption><span>Incidence of Treatment-Emergent Adverse Experiences in Placebo-Controlled Clinical Trials Lasting up to 10 Nights(Percentage of patients reporting)</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<thead>
<tr class="First">
<td align="left" colspan="1" valign="top"><p class="First"><span class="Bold"></span></p></td>
<td align="center" colspan="1" valign="top">Zolpidem </td>
<td align="left" colspan="1" valign="top"><p class="First"><span class="Bold"></span></p></td>
</tr>
<tr>
<td align="left" colspan="1" valign="top">Body System/ </td>
<td align="center" colspan="1" valign="top">(≤10 mg) </td>
<td align="center" colspan="1" valign="top">Placebo </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" valign="top">Adverse Event* </td>
<td class="Botrule" align="center" colspan="1" valign="top">(N=685) </td>
<td class="Botrule" align="center" colspan="1" valign="top">(N=473) </td>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="3"><p class="First Footnote">*Reactions reported by at least 1% of patients treated with zolpidem tartrate tablets and at a greater frequency than placebo. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Central and Peripheral Nervous System </td>
<td class="Toprule" align="left" valign="top"><p class="First"><span class="Bold"></span></p></td>
<td class="Toprule" align="left" valign="top"><p class="First"><span class="Bold"></span></p></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td align="center" valign="top">7 </td>
<td align="center" valign="top">6 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> </td>
<td align="center" valign="top">2 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td align="center" valign="top">1 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top">Gastrointestinal System </td>
<td align="left" valign="top"><p class="First"><span class="Bold"></span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold"></span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Botrule" align="center" valign="top">1 </td>
<td class="Botrule" align="center" valign="top">- </td>
</tr>
</tbody>
</table>
<p>The following table was derived from results of three placebo-controlled long-term efficacy trials involving zolpidem tartrate tablets. These trials involved patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> who were treated for 28 to 35 nights with zolpidem at doses of 5, 10, or 15 mg. The table is limited to data from doses up to and including 10 mg, the highest dose recommended for use. The table includes only adverse events occurring at an incidence of at least 1% for zolpidem patients.</p>
<a name="ID55"></a><table width="99%">
<caption><span>Incidence of Treatment-Emergent Adverse Experiences in Placebo-Controlled Clinical Trials Lasting up to 35 Nights(Percentage of patients reporting)</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<thead>
<tr class="First">
<td align="left" colspan="1" valign="top"></td>
<td align="center" colspan="1" valign="top">Zolpidem </td>
<td align="left" colspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" valign="top">Body System/ </td>
<td align="center" colspan="1" valign="top">(≤10 mg) </td>
<td align="center" colspan="1" valign="top">Placebo </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" valign="top">Adverse Event* </td>
<td class="Botrule" align="center" colspan="1" valign="top">(N=152) </td>
<td class="Botrule" align="center" colspan="1" valign="top">(N=161) </td>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="3"><p class="First Footnote">*Reactions reported by at least 1% of patients treated with zolpidem tartrate tablets and at a greater frequency than placebo. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Autonomic Nervous System </td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">   Dry mouth </td>
<td align="center" valign="top">3 </td>
<td align="center" valign="top">1 </td>
</tr>
<tr>
<td align="left" valign="top">Body as a Whole </td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> </td>
<td align="center" valign="top">4 </td>
<td align="center" valign="top">1 </td>
</tr>
<tr>
<td align="left" valign="top">   Back <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td align="center" valign="top">3 </td>
<td align="center" valign="top">2 </td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms </td>
<td align="center" valign="top">2 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top">   Chest <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </td>
<td align="center" valign="top">1 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top">Cardiovascular System </td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span> </td>
<td align="center" valign="top">2 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top">Central and Peripheral Nervous System </td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> </td>
<td align="center" valign="top">8 </td>
<td align="center" valign="top">5 </td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td align="center" valign="top">5 </td>
<td align="center" valign="top">1 </td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span> </td>
<td align="center" valign="top">3 </td>
<td align="center" valign="top">1 </td>
</tr>
<tr>
<td align="left" valign="top">   Drugged feeling </td>
<td align="center" valign="top">3 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span> </td>
<td align="center" valign="top">2 </td>
<td align="center" valign="top">1 </td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> </td>
<td align="center" valign="top">2 </td>
<td align="center" valign="top">1 </td>
</tr>
<tr>
<td align="left" valign="top">   Abnormal dreams </td>
<td align="center" valign="top">1 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span> </td>
<td align="center" valign="top">1 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top">   Sleep disorder </td>
<td align="center" valign="top">1 </td>
<td align="center" valign="top">- </td>
</tr>
<tr>
<td align="left" valign="top">Gastrointestinal System </td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center" valign="top">3 </td>
<td align="center" valign="top">2 </td>
</tr>
<tr>
<td align="left" valign="top">   Abdominal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </td>
<td align="center" valign="top">2 </td>
<td align="center" valign="top">2 </td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td align="center" valign="top">2 </td>
<td align="center" valign="top">1 </td>
</tr>
<tr>
<td align="left" valign="top">Respiratory System </td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </td>
<td align="center" valign="top">4 </td>
<td align="center" valign="top">2 </td>
</tr>
<tr>
<td align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </td>
<td align="center" valign="top">3 </td>
<td align="center" valign="top">1 </td>
</tr>
<tr>
<td align="left" valign="top">Skin and Appendages </td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td class="Botrule" align="center" valign="top">2 </td>
<td class="Botrule" align="center" valign="top">1 </td>
</tr>
</tbody>
</table>
<p><span class="Bold">Dose relationship for adverse reactions: </span>There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse reactions associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse events.</p>
<p><span class="Bold">Adverse event incidence across the entire preapproval database: </span>Zolpidem tartrate tablets were administered to 3,660 subjects in clinical trials throughout the U.S., Canada, and Europe. Treatment-emergent adverse events associated with clinical trial participation were recorded by clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals experiencing treatment-emergent adverse events, similar types of untoward events were grouped into a smaller number of standardized event categories and classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms.</p>
<p>The frequencies presented, therefore, represent the proportions of the 3,660 individuals exposed to zolpidem, at all doses, who experienced an event of the type cited on at least one occasion while receiving zolpidem. All reported treatment-emergent adverse events are included, except those already listed in the table above of adverse events in placebo-controlled studies, those coding terms that are so general as to be uninformative, and those events where a drug cause was remote. It is important to emphasize that, although the events reported did occur during treatment with zolpidem tartrate tablets, they were not necessarily caused by it.</p>
<p>Adverse events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.</p>
<p><span class="Italics">Autonomic nervous system: </span>Infrequent: increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. Rare: abnormal accommodation, <span class="product-label-link" type="condition" conceptid="27587" conceptname="Disturbance of salivary secretion">altered saliva</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, increased saliva, tenesmus.</p>
<p><span class="Italics">Body as a whole: </span>Frequent: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. Rare: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy aggravated</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, increased ESR, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless legs</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, tolerance increased, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>.</p>
<p><span class="Italics">Cardiovascular system: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Rare: <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertension aggravated</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>.</p>
<p><span class="Italics">Central and peripheral nervous system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, decreased cognition, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4238753" conceptname="Optical illusion">illusion</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, sleeping (after daytime dosing), speech disorder, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. Rare: <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, appetite increased, decreased libido, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">dysphasia</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling strange</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>, intoxicated feeling, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>.</p>
<p><span class="Italics">Gastrointestinal system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Rare: <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="134681" conceptname="Diffuse spasm of esophagus">esophagospasm</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries</span>.</p>
<p><span class="Italics">Hematologic and lymphatic system: </span>Rare: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4049428" conceptname="Hemoglobinemia">hyperhemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4308125" conceptname="Macrocytic anemia">macrocytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
<p><span class="Italics">Immunologic system: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Rare: <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<p><span class="Italics">Liver and biliary system: </span>Infrequent: abnormal hepatic function, increased SGPT. Rare: <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>.</p>
<p><span class="Italics">Metabolic and nutritional: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>. Rare: <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesteremia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, increased alkaline phosphatase, increased BUN, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>.</p>
<p><span class="Italics">Musculoskeletal system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>. Rare: <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="372409" conceptname="Sciatica">sciatica</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>.</p>
<p><span class="Italics">Reproductive system: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>. Rare: <span class="product-label-link" type="condition" conceptid="4116072" conceptname="Fibroadenoma of breast">breast fibroadenosis</span>, breast neoplasm, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>.</p>
<p><span class="Italics">Respiratory system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. Rare: <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
<p><span class="Italics">Skin and appendages: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. Rare: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, injection-site <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Special senses: </span>Frequent: <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. Rare: <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span>, <span class="product-label-link" type="condition" conceptid="379814" conceptname="Dislocation of lacrimal gland">lacrimation abnormal</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">photopsia</span>.</p>
<p><span class="Italics">Urogenital system: </span>Frequent: <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. Infrequent: <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>. Rare: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, micturition frequency, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID59"></a><a name="section-7"></a><p></p>
<h1>7. Drug Interactions:</h1>
<div class="Section">
<a name="ID60"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CNS active drugs</h2>
<p class="First">Since the systematic evaluations of zolpidem in combination with other CNS-active drugs have been limited, careful consideration should be given to the pharmacology of any CNS-active drug to be used with zolpidem. Any drug with CNS-depressant effects could potentially enhance the CNS-depressant effect of zolpidem.</p>
<p>Zolpidem tartrate tablets were evaluated in healthy subjects in single-dose interaction studies for several CNS drugs. Imipramine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>, but there was an additive effect of decreased alertness and psychomotor performance. A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict a lack following chronic administration.</p>
<p>An additive effect on psychomotor performance between alcohol and zolpidem was demonstrated <span class="Italics">[see <a href="#ID41">Warnings and Precautions (5.5)</a>].</span></p>
<p>A single-dose interaction study with zolpidem 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span>. When multiple doses of zolpidem and fluoxetine at steady-state concentrations were evaluated in healthy females, the only significant change was a 17% increase in the zolpidem half-life. There was no evidence of an additive effect in psychomotor performance.</p>
<p>Following five consecutive nightly doses of zolpidem 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem C<span class="Sub">max</span> was significantly higher (43%) and T<span class="Sub">max</span> was significantly decreased (53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.</p>
</div>
<div class="Section">
<a name="ID62"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs that affect drug metabolism via cytochrome P450</h2>
<p class="First">Some compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes has not been carefully evaluated.</p>
<p>A randomized, double-blind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zolpidem (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUC<span class="Sub">0-∞</span> of zolpidem. There were no significant pharmacodynamic effects of zolpidem on subjective <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, postural sway, or psychomotor performance.</p>
<p>A randomized, placebo-controlled, crossover interaction study in eight healthy female subjects between five consecutive daily doses of rifampin (600 mg) and a single dose of zolpidem (20 mg) given 17 hours after the last dose of rifampin showed significant reductions of the AUC (–73%), C<span class="Sub">max </span>(–58%), and T<span class="Sub">1/2</span> (–36%) of zolpidem together with significant reductions in the pharmacodynamic effects of zolpidem.</p>
<p>A randomized double-blind crossover interaction study in twelve healthy subjects showed that co-administration of a single 5 mg dose of zolpidem tartrate with ketoconazole, a potent CYP3A4 inhibitor, given as 200 mg twice daily for 2 days increased C<span class="Sub">max</span> of zolpidem by a factor of 1.3 and increased the total AUC of zolpidem by a factor of 1.7 compared to zolpidem alone and prolonged the elimination half-life by approximately 30% along with an increase in the pharmacodynamic effects of zolpidem. Caution should be used when ketoconazole is given with zolpidem and consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together. Patients should be advised that use of zolpidem tartrate tablets with ketoconazole may enhance the sedative effects.</p>
</div>
<div class="Section">
<a name="ID64"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Other drugs with no interaction with zolpidem</h2>
<p class="First">A study involving cimetidine/zolpidem and ranitidine/zolpidem combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.</p>
<p>Zolpidem had no effect on digoxin pharmacokinetics and did not affect <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when given with warfarin in normal subjects.</p>
</div>
<div class="Section">
<a name="ID66"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drug-laboratory tests interactions</h2>
<p class="First">Zolpidem is not known to interfere with commonly employed clinical laboratory tests. In addition, clinical data indicate that zolpidem does not cross-react with benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard <span class="product-label-link" type="condition" conceptid="4215138" conceptname="Drug screening test">urine drug screens</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID70"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID71"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies of zolpidem tartrate tablets in pregnant women. Zolpidem tartrate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Administration of zolpidem to pregnant rats and rabbits resulted in adverse effects on offspring development at doses greater than the zolpidem tartrate tablets maximum recommended human dose (MRHD) of 10 mg/day (approximately 8 mg/day zolpidem base); however, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was not observed.</p>
<p>When zolpidem was administered at oral doses of 4, 20, and 100 mg base/kg (approximately 5, 24 and 120 times the MRHD on a mg/m<span class="Sup">2</span> basis) to pregnant rats during the period of organogenesis, dose-related decreases in fetal skull ossification occurred at all but the lowest dose, which is approximately 5 times the MRHD on a mg/m<span class="Sup">2</span> basis. In rabbits treated during organogenesis with zolpidem at oral doses of 1, 4, and 16 mg base/kg (approximately 2.5, 10 and 40 times the MRHD on a mg/m<span class="Sup">2</span> basis), increased embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and incomplete fetal skeletal ossification occurred at the highest dose. The no-effect dose for embryo-fetal toxicity in rabbits is approximately 10 times the MRHD on a mg/m<span class="Sup">2</span> basis. Administration of zolpidem to rats at oral doses of 4, 20, and 100 mg base/kg (approximately 5, 24 and 120 times the MRHD on a mg/m<span class="Sup">2</span> basis) during the latter part of pregnancy and throughout lactation produced decreased offspring growth and survival at all but the lowest dose, which is approximately 5 times the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
<p><span class="Bold Italics Underline">Neonatal Complications</span></p>
<p>Studies in children to assess the effects of prenatal exposure to zolpidem have not been conducted; however, cases of severe <span class="product-label-link" type="condition" conceptid="4318857" conceptname="Neonatal respiratory depression">neonatal respiratory depression</span> have been reported when zolpidem was used at the end of pregnancy, especially when taken with other CNS depressants.</p>
<p>Children born to mothers taking sedative-hypnotic drugs may be at some risk for withdrawal symptoms during the postnatal period. Neonatal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span> has also been reported in infants born to mothers who received sedative-hypnotic drugs during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID73"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and delivery</h2>
<p class="First">Zolpidem tartrate tablets have no established use in labor and delivery <span class="Italics">[see <a href="#ID71">Pregnancy (8.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID75"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing mothers</h2>
<p class="First">Zolpidem is excreted in human milk. Studies in lactating mothers indicate that the half-life of zolpidem is similar to that in non-lactating women (2.6 ± 0.3 hr). The effect of zolpidem on the nursing infant is not known. Caution should be exercised when zolpidem tartrate tablets are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID77"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric use</h2>
<p class="First">Safety and effectiveness of zolpidem have not been established in pediatric patients.</p>
<p>In an 8-week controlled study, 201 pediatric patients (aged 6-17 years) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> associated with attention-deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> disorder (90% of the patients were using psychoanaleptics) were treated with an oral solution of zolpidem (n=136), or placebo (n=65). Zolpidem did not significantly decrease latency to persistent sleep, compared to placebo, as measured by polysomnography after 4 weeks of treatment. Psychiatric and <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">nervous system disorders</span> comprised the most frequent (&gt; 5%) treatment emergent adverse reactions observed with zolpidem versus placebo and included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (23.5% vs. 1.5%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (12.5% vs. 9.2%), and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (7.4% vs. 0%) <span class="Italics">[see <a href="#ID43">Warnings and Precautions (5.6)</a>]. </span>Ten patients on zolpidem (7.4%) discontinued treatment due to an adverse reaction.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID79"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric use</h2>
<p class="First">A total of 154 patients in U.S. controlled clinical trials and 897 patients in non-U.S. clinical trials who received zolpidem were ≥60 years of age. For a pool of U.S. patients receiving zolpidem at doses of ≤10 mg or placebo, there were three adverse reactions occurring at an incidence of at least 3% for zolpidem and for which the zolpidem incidence was at least twice the placebo incidence (i.e., they could be considered drug related).</p>
<a name="ID81"></a><table width="99%">
<col width="33%">
<col width="33%">
<col width="33%">
<thead><tr class="First Last">
<td class="Botrule" align="center" colspan="1" valign="top"><p class="First"><span class="Bold">Adverse Event </span></p></td>
<td class="Botrule" align="center" colspan="1" valign="top"><p class="First"><span class="Bold">Zolpidem </span></p></td>
<td class="Botrule" align="center" colspan="1" valign="top"><p class="First"><span class="Bold">Placebo </span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td class="Toprule" align="center" valign="top">3% </td>
<td class="Toprule" align="center" valign="top">0% </td>
</tr>
<tr>
<td align="center" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> </td>
<td align="center" valign="top">5% </td>
<td align="center" valign="top">2% </td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Botrule" align="center" valign="top">3% </td>
<td class="Botrule" align="center" valign="top">1% </td>
</tr>
</tbody>
</table>
<p>A total of 30/1,959 (1.5%) non-U.S. patients receiving zolpidem reported <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>, including 28/30 (93%) who were ≥70 years of age. Of these 28 patients, 23 (82%) were receiving zolpidem doses &gt;10 mg. A total of 24/1,959 (1.2%) non-U.S. patients receiving zolpidem reported <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, including 18/24 (75%) who were ≥70 years of age. Of these 18 patients, 14 (78%) were receiving zolpidem doses &gt;10 mg.</p>
<p>The dose of zolpidem tartrate tablets in elderly patients is 5 mg to minimize adverse effects related to impaired motor and/or cognitive performance and unusual sensitivity to sedative/hypnotic drugs <span class="Italics">[see <a href="#ID43">Warnings and Precautions (5.6)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="ID85"></a><a name="section-9"></a><p></p>
<h1>9. DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="ID86"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled substance</h2>
<p class="First">Zolpidem tartrate is classified as a Schedule IV controlled substance by federal regulation.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="ID88"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug effects over time. Tolerance may occur to both desired and undesired effects of drugs and may develop at different rates for different effects. </p>
<p>Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. Its characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, using a multidisciplinary approach, but relapse is common.</p>
<p>Studies of abuse potential in former drug abusers found that the effects of single doses of zolpidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while zolpidem tartrate 10 mg was difficult to distinguish from placebo.</p>
<p>Because persons with a history of addiction to, or abuse of, drugs or alcohol are at increased risk for misuse, abuse and addiction of zolpidem, they should be monitored carefully when receiving zolpidem or any other hypnotic.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="ID90"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.</p>
<p>Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to a withdrawal syndrome  that may include abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The following adverse events which are considered to meet the DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal were reported during U.S. clinical trials following placebo substitution occurring within 48 hours following last zolpidem treatment: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>. These reported adverse events occurred at an incidence of 1% or less. However, available data cannot provide a reliable estimate of the incidence, if any, of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> during treatment at recommended doses. Post-marketing reports of abuse, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and withdrawal have been received.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID92"></a><a name="section-10"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<div class="Section">
<a name="ID93"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Signs and symptoms</h2>
<p class="First">In postmarketing experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with zolpidem tartrate alone, or in combination with CNS-depressant agents, impairment of consciousness ranging from <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, cardiovascular and/or respiratory compromise, and fatal outcomes have been reported.</p>
</div>
<div class="Section">
<a name="ID95"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Recommended treatment</h2>
<p class="First">General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Zolpidem’s sedative hypnotic effect was shown to be reduced by flumazenil and therefore may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>). As in all cases of drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.</p>
<p>As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID97"></a><a name="section-11"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">Zolpidem tartrate is a non-benzodiazepine hypnotic of the imidazopyridine class and is available in 5 mg and 10 mg strength tablets for oral administration.</p>
<p>Chemically, zolpidem is N,N,6-trimethyl-2-p-tolylimidazo[1,2-a] pyridine-3-acetamide L-(+)-tartrate (2:1). It has the following structure:</p>
<div class="Figure"><img alt="Image 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b87ea23e-2d54-4d10-8f10-72d4c62f3245&amp;name=zolpidem-01.jpg"></div>
<p>Zolpidem tartrate, USP is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. It has a molecular weight of 764.88.</p>
<p>Each zolpidem tartrate tablet, USP includes the following inactive ingredients: hypromellose, lactose monohydrate, microcrystalline cellulose, magnesium stearate, polyethylene glycol, sodium starch glycolate, titanium dioxide and ferric oxide red; the 10 mg tablet also contains ferric oxide yellow.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID101"></a><a name="section-12"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID102"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of action</h2>
<p class="First">Zolpidem, the active moiety of zolpidem tartrate, is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties. It interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes, zolpidem <span class="Italics">in vitro</span> binds the BZ<span class="Sub">1</span> receptor preferentially with a high affinity ratio of the α<span class="Sub">1</span>/α<span class="Sub">5</span> subunits. This selective binding of zolpidem on the BZ<span class="Sub">1</span> receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem tartrate at hypnotic doses.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID104"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetic profile of zolpidem tartrate tablets is characterized by rapid absorption from the gastrointestinal tract and a short elimination half-life (T<span class="Sub">1/2</span>) in healthy subjects.</p>
<p>In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (C<span class="Sub">max</span>) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (T<span class="Sub">max</span>) of 1.6 hours for both. The mean zolpidem tartrate tablets elimination half-life was 2.6 (range: 1.4 to 4.5) and 2.5 (range: 1.4 to 3.8) hours, for the 5 and 10 mg tablets, respectively. Zolpidem tartrate tablets are converted to inactive metabolites that are eliminated primarily by renal excretion. Zolpidem tartrate tablets demonstrated linear kinetics in the dose range of 5 to 20 mg. Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL. Zolpidem did not accumulate in young adults following nightly dosing with 20 mg zolpidem tartrate tablets for 2 weeks.</p>
<p>A food-effect study in 30 healthy male subjects compared the pharmacokinetics of zolpidem tartrate tablets 10 mg when administered while fasting or 20 minutes after a meal. Results demonstrated that with food, mean AUC and C<span class="Sub">max</span> were decreased by 15% and 25%, respectively, while mean T<span class="Sub">max</span> was prolonged by 60% (from 1.4 to 2.2 hr). The half-life remained unchanged. These results suggest that, for faster sleep onset, zolpidem tartrate tablets should not be administered with or immediately after a meal.</p>
<p><span class="Italics">Special Populations</span></p>
<p><span class="Italics">Elderly:</span></p>
<p>In the elderly, the dose for zolpidem tartrate tablets should be 5 mg <span class="Italics">[see <a href="#ID32">Warnings and Precautions (5)</a> and <a href="#ID9">Dosage and Administration (2)</a>]. </span>This recommendation is based on several studies in which the mean C<span class="Sub">max</span>, T<span class="Sub">1/2</span>, and AUC were significantly increased when compared to results in young adults. In one study of eight elderly subjects (&gt;70 years), the means for C<span class="Sub">max</span>, T<span class="Sub">1/2</span>, and AUC significantly increased by 50% (255 vs. 384 ng/mL), 32% (2.2 vs. 2.9 hr), and 64% (955 vs. 1,562 ng·hr/mL), respectively, as compared to younger adults (20 to 40 years) following a single 20 mg oral dose. Zolpidem tartrate tablets did not accumulate in elderly subjects following nightly oral dosing of 10 mg for 1 week.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span></p>
<p>The pharmacokinetics of zolpidem tartrate tablets in eight patients with chronic <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> were compared to results in healthy subjects. Following a single 20 mg oral zolpidem tartrate dose, mean C<span class="Sub">max</span> and AUC were found to be two times (250 vs. 499 ng/mL) and five times (788 vs. 4,203 ng·hr/mL) higher, respectively, in hepatically- compromised patients. T<span class="Sub">max</span> did not change. The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr). Dosing should be modified accordingly in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics">[see <a href="#ID12">Dosage and Administration (2.2)</a> and <a href="#ID43">Warnings and Precautions (5.6)</a>].</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span></p>
<p>The pharmacokinetics of zolpidem tartrate were studied in 11 patients with end-stage <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (mean Cl<span class="Sub">Cr</span> = 6.5 ± 1.5 mL/min) undergoing hemodialysis three times a week, who were dosed with zolpidem tartrate 10 mg orally each day for 14 or 21 days. No statistically significant differences were observed for C<span class="Sub">max</span>, T<span class="Sub">max</span>, half-life, and AUC between the first and last day of drug administration when baseline concentration adjustments were made. On day 1, C<span class="Sub">max</span> was 172 ± 29 ng/mL (range: 46 to 344 ng/mL). After repeated dosing for 14 or 21 days, C<span class="Sub">max</span> was 203 ± 32 ng/mL (range: 28 to 316 ng/mL). On day 1, T<span class="Sub">max</span> was 1.7 ± 0.3 hr (range: 0.5 to 3.0 hr); after repeated dosing T<span class="Sub">max</span> was 0.8 ± 0.2 hr (range: 0.5 to 2.0 hr). This variation is accounted for by noting that last-day serum sampling began 10 hours after the previous dose, rather than after 24 hours. This resulted in residual drug concentration and a shorter period to reach maximal serum concentration. On day 1, T<span class="Sub">1/2 </span>was 2.4 ± 0.4 hr (range: 0.4 to 5.1 hr). After repeated dosing, T<span class="Sub">1/2 </span>was 2.5 ± 0.4 hr (range: 0.7 to 4.2 hr). AUC was 796 ± 159 ng·hr/mL after the first dose and 818 ± 170 ng·hr/mL after repeated dosing. Zolpidem was not hemodialyzable. No accumulation of unchanged drug appeared after 14 or 21 days. Zolpidem pharmacokinetics were not significantly different in renally impaired patients. No dosage adjustment is necessary in patients with compromised renal function. However, as a general precaution, these patients should be closely monitored.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID106"></a><a name="section-13"></a><p></p>
<h1>13. NONCLINICAL  TOXICOLOGY</h1>
<div class="Section">
<a name="ID107"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis:</span>  Zolpidem was administered to mice and rats for 2 years at dietary dosages of 4, 18, and 80 mg base/kg. In mice, these doses are approximately 2.5, 10, and 50 times the maximum recommended human dose (MRHD) of 10 mg/day (8 mg zolpidem base) on mg/m<span class="Sup">2</span> basis. In rats, these doses are approximately 5, 20, and 100 times the MRHD on a mg/m<span class="Sup">2</span> basis. No evidence of carcinogenic potential was observed in mice. In rats, renal tumors (<span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipoma</span>, liposarcoma) were seen at the mid- and high doses.</p>
<p><span class="Italics">Mutagenesis:</span>  Zolpidem was negative in <span class="Italics">in vitro</span> (bacterial reverse mutation, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and chromosomal aberration) and <span class="Italics">in vivo</span> (mouse micronucleus) genetic toxicology assays.</p>
<p><span class="Italics">Impairment of fertility:</span>  Oral administration of zolpidem (doses of 4, 20, and 100 mg base/kg or approximately 5, 24, and 120 times the MRHD on a mg/m<span class="Sup">2</span> basis) to rats prior to and during mating, and continuing in females through postpartum day 25, resulted in irregular estrus cycles and prolonged precoital intervals. The no-effect dose for these findings is approximately 24 times the MRHD on a mg/m<span class="Sup">2</span> basis. There was no impairment of fertility at any dose tested.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID109"></a><a name="section-14"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<div class="Section">
<a name="ID110"></a><a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Transient insomnia</span></h2>
<p class="First">Normal adults experiencing <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">transient insomnia</span> (n = 462) during the first night in a sleep laboratory were evaluated in a double-blind, parallel group, single-night trial comparing two doses of zolpidem (7.5 and 10 mg) and placebo. Both zolpidem doses were superior to placebo on objective (polysomnographic) measures of sleep latency, sleep duration, and number of awakenings.</p>
<p>Normal elderly adults (mean age 68) experiencing <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">transient insomnia</span> (n = 35) during the first two nights in a sleep laboratory were evaluated in a double-blind, crossover, 2-night trial comparing four doses of zolpidem (5, 10, 15 and 20 mg) and placebo. All zolpidem doses were superior to placebo on the two primary PSG parameters (sleep latency and efficiency) and all four subjective outcome measures (sleep duration, sleep latency, number of awakenings, and sleep quality).</p>
</div>
<div class="Section">
<a name="ID112"></a><a name="section-14.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Chronic insomnia</span></h2>
<p class="First">Zolpidem was evaluated in two controlled studies for the treatment of patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> (most closely resembling primary <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, as defined in the APA Diagnostic and Statistical Manual of <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Mental Disorders</span>, DSM-IV™). Adult outpatients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> (n = 75) were evaluated in a double-blind, parallel group, 5-week trial comparing two doses of zolpidem tartrate and placebo. On objective (polysomnographic) measures of sleep latency and sleep efficiency, zolpidem 10 mg was superior to placebo on sleep latency for the first 4 weeks and on sleep efficiency for weeks 2 and 4. Zolpidem was comparable to placebo on number of awakenings at both doses studied.</p>
<p>Adult outpatients (n=141) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> were also evaluated, in a double-blind, parallel group, 4-week trial comparing two doses of zolpidem and placebo. Zolpidem 10 mg was superior to placebo on a subjective measure of sleep latency for all 4 weeks, and on subjective measures of total sleep time, number of awakenings, and sleep quality for the first treatment week.</p>
<p>Increased <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">wakefulness</span> during the last third of the night as measured by polysomnography has not been observed in clinical trials with zolpidem tartrate tablets.</p>
</div>
<div class="Section">
<a name="ID114"></a><a name="section-14.3"></a><p></p>
<h2>14.3 Studies pertinent to safety concerns for sedative/hypnotic drugs</h2>
<p class="First"><span class="Italics">Next-day residual effects: </span>Next-day residual effects of zolpidem tartrate tablets were evaluated in seven studies involving normal subjects. In three studies in adults (including one study in a phase advance model of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">transient insomnia</span>) and in one study in elderly subjects, a small but statistically significant decrease in performance was observed in the Digit Symbol Substitution Test (DSST) when compared to placebo. Studies of zolpidem tartrate tablets in non-elderly patients with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> did not detect evidence of next-day residual effects using the DSST, the Multiple Sleep Latency Test (MSLT), and patient ratings of alertness.</p>
<p><span class="Italics">Rebound effects: </span>There was no objective (polysomnographic) evidence of rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> at recommended doses seen in studies evaluating sleep on the nights following discontinuation of zolpidem tartrate tablets. There was subjective evidence of impaired sleep in the elderly on the first post-treatment night at doses above the recommended elderly dose of 5 mg.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory impairment</span>: </span>Controlled studies in adults utilizing objective measures of memory yielded no consistent evidence of next-day <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span> following the administration of zolpidem tartrate tablets. However, in one study involving zolpidem doses of 10 and 20 mg, there was a significant decrease in next-morning recall of information presented to subjects during peak drug effect (90 minutes post-dose), i.e., these subjects experienced <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span>. There was also subjective evidence from adverse event data for <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span> occurring in association with the administration of zolpidem tartrate tablets, predominantly at doses above 10 mg.</p>
<p><span class="Italics">Effects on sleep stages: </span>In studies that measured the percentage of sleep time spent in each sleep stage, zolpidem tartrate tablets have generally been shown to preserve sleep stages. Sleep time spent in stages 3 and 4 (deep sleep) was found comparable to placebo with only inconsistent, minor changes in REM (paradoxical) sleep at the recommended dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID116"></a><a name="section-15"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Zolpidem tartrate 5 mg tablets, USP are red colored, capsule shaped tablets with the Torrent logo debossed on one side and ‘5 MG’ debossed on the other side and supplied as:</p>
<p>NDC NumberSize</p>
<p>16590-528-15                                                                              bottle of 15</p>
<p>16590-528-20                                                                              bottle of 20</p>
<p>16590-528-25                                                                              bottle of 25</p>
<p>16590-528-30                                                                              bottle of 30</p>
<p>16590-528-40                                                                              bottle of 40</p>
<p>16590-528-56                                                                              bottle of 56</p>
<p>16590-528-60                                                                              bottle of 60</p>
<p>16590-528-90                                                                              bottle of 90</p>
<p>Zolpidem tartrate 10 mg tablets, USP are peach-yellow colored, capsule shaped tablets with the Torrent logo debossed on one side and ‘10 MG’ debossed on the other side and supplied as:</p>
<p>NDC NumberSize</p>
<p>16590-527-15                                                                              bottle of 15</p>
<p>16590-527-20                                                                              bottle of 20</p>
<p>16590-527-28                                                                              bottle of 28</p>
<p>16590-527-30                                                                              bottle of 30</p>
<p>16590-527-45                                                                              bottle of 45</p>
<p>16590-527-60                                                                              bottle of 60</p>
<p>16590-527-90                                                                              bottle of 90</p>
<p>Store at 20°-25°C (68°-77°F); excursions permitted to 15° - 30°C (59°- 86°F) [see USP Controlled Room Temperature].</p>
<p></p>
<p><span class="Bold">Relabeling and Repackaging by:</span></p>
<p>STAT Rx USA LLC</p>
<p>Gainesville, GA  30501</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID118"></a><a name="section-16"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<p class="First">Prescribers or other healthcare professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with sedative-hypnotics, should counsel them in its appropriate use, and should instruct them to read the accompanying Medication Guide <span class="Italics">[see <a href="#ID126">Medication Guide (17.4)</a>].</span></p>
<div class="Section">
<a name="ID120"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Severe <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span></h2>
<p class="First">Inform patients that severe anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred with zolpidem. Describe the signs/symptoms of these reactions and advise patients to seek medical attention immediately if any of them occur.</p>
</div>
<div class="Section">
<a name="ID122"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Sleep-driving and other complex behaviors</h2>
<p class="First">There have been reports of people getting out of bed after taking a sedative-hypnotic and driving their cars while not fully awake, often with no memory of the event. If a patient experiences such an episode, it should be reported to his or her doctor immediately, since "sleep-driving" can be dangerous. This behavior is more likely to occur when zolpidem tartrate tablets are taken with alcohol or other central nervous system depressants <span class="Italics">[see <a href="#ID37">Warnings and Precautions (5.3)</a>]. </span>Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with "sleep-driving", patients usually do not remember these events.</p>
<p>In addition, patients should be advised to report all concomitant medications to the prescriber. Patients should be instructed to report events such as "sleep-driving" and other complex behaviors immediately to the prescriber.</p>
</div>
<div class="Section">
<a name="ID124"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Administration instructions</h2>
<p class="First">Patients should be counseled to take zolpidem tartrate tablets right before they get into bed and only when they are able to stay in bed a full night (7-8 hours) before being active again. Zolpidem tartrate tablets should not be taken with or immediately after a meal. Advise patients NOT to take zolpidem tartrate tablets when drinking alcohol.</p>
</div>
<div class="Section">
<a name="ID126"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Medication Guide</h2>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID999"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Zolpidem Tartrate Tablets, USP  C-IV</span></p>
<p>Read the Medication Guide that comes with zolpidem tartrate tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about zolpidem tartrate tablets?</span></p>
<p><span class="Bold">After taking zolpidem tartrate tablets</span>, <span class="Bold">you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning</span>, <span class="Bold">you may not remember that you did anything during the night. </span>You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> with zolpidem tartrate tablets. Reported activities include:</p>
<ul>
<li>driving a car ("sleep-driving")</li>
<li>making and eating food</li>
<li>talking on the phone</li>
<li>having sex</li>
<li>sleep-walking</li>
</ul>
<p><span class="Bold">Call your doctor right away if you find out that you have done any of the above activities after taking zolpidem tartrate tablets.</span></p>
<p><span class="Bold">Important:</span></p>
<p><span class="Bold">1. Take zolpidem tartrate tablets exactly as prescribed</span></p>
<ul>
<li>Do not take more zolpidem tartrate tablets than prescribed.</li>
<li>Take zolpidem tartrate tablets right before you get in bed, not sooner.</li>
</ul>
<p><span class="Bold">2. Do not take zolpidem tartrate tablets if you:</span></p>
<ul>
<li>drink alcohol</li>
<li>take other medicines that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take zolpidem tartrate tablets with your other  medicines.</li>
<li>cannot get a full night’s sleep</li>
</ul>
<p><span class="Bold">What are zolpidem tartrate tablets?</span></p>
<p>Zolpidem tartrate tablets are a sedative-hypnotic (sleep) medicine. Zolpidem tartrate tablets are used in adults for the short-term treatment of a <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problem</span> called <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. Symptoms of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> include:</p>
<ul><li>trouble <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep</li></ul>
<p>Zolpidem tartrate tablets are not for children.</p>
<a name="ID136"></a><table width="48%">
<col width="48%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left">Zolpidem tartrate is a federally controlled substance (C-IV) <br>because it can be abused or lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Keep <br>zolpidem tartrate tablets in a safe place to prevent misuse <br>and abuse. Selling or giving away zolpidem tartrate tablets <br>may harm others, and is against the law. Tell your doctor if <br>you have ever abused or have been dependent on alcohol, <br>prescription medicines or street drugs. </td></tr></tbody>
</table>
<p><span class="Bold">Who should not take zolpidem tartrate tablets?</span></p>
<p>Do not take zolpidem tartrate tablets if you are allergic to anything in it.</p>
<p>See the end of this Medication Guide for a complete list of ingredients in zolpidem tartrate tablets.</p>
<p><span class="Bold">Zolpidem tartrate tablets may not be right for you. Before starting zolpidem tartrate tablets</span>, <span class="Bold">tell your doctor about all of your health conditions</span>, <span class="Bold">including if you:</span></p>
<ul>
<li>have a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mental illness, or suicidal thoughts</li>
<li>have a history of drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> or addiction</li>
<li>have kidney or liver disease</li>
<li>have a <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> or breathing problems</li>
<li>are pregnant, planning to become pregnant, or breastfeeding</li>
</ul>
<p>Tell your doctor about all of the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Medicines can interact with each other, sometimes causing serious side effects. <span class="Bold">Do not take zolpidem tartrate tablets with other medicines that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>.</span></p>
<p>Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How should I take zolpidem tartrate tablets?</span></p>
<ul>
<li>Take zolpidem tartrate tablets exactly as prescribed. Do not take more zolpidem tartrate tablets than prescribed for you.</li>
<li><span class="Bold">Take zolpidem tartrate tablets right before you get into bed.</span></li>
<li><span class="Bold">Do not take zolpidem tartrate tablets unless you are able to stay in bed a full night (7-8 hours) before you must be active again.</span></li>
<li>For faster sleep onset, zolpidem tartrate tablets should NOT be taken with or immediately after a meal.</li>
<li>Call your doctor if your <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problem</span>.</li>
<li>If you take too much zolpidem tartrate tablets or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or poison control center right away, or get emergency treatment.</li>
</ul>
<p><span class="Bold">What are the possible side effects of zolpidem tartrate tablets?</span></p>
<p><span class="Bold">Serious side effects of zolpidem tartrate tablets include:</span></p>
<ul>
<li>
<span class="Bold">getting out of bed while not being fully awake and do an activity that you do not know you are doing. </span>(See "What is the most important information I should know about zolpidem tartrate tablets?)</li>
<li>
<span class="Bold">abnormal thoughts and behavior. </span>Symptoms include more outgoing or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> than normal, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and suicidal thoughts or actions.</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></span></li>
<li>
<span class="Bold">severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Symptoms include <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat, trouble breathing, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Get emergency medical help if you get these symptoms after taking zolpidem tartrate tablets.</li>
</ul>
<p><span class="Bold">Call your doctor right away if you have any of the above side effects or any other side effects that <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you while using zolpidem tartrate tablets.</span></p>
<p><span class="Bold">The most common side effects of zolpidem tartrate tablets are:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>"drugged feelings"</li>
<li>You may still feel drowsy the next day after taking zolpidem tartrate tablets. <span class="Bold">Do not drive or do other dangerous activities after taking zolpidem tartrate tablets until you feel fully awake.</span>
</li>
</ul>
<p><span class="Bold">After you stop taking a sleep medicine</span>, you may have symptoms for 1 to 2 days such as: trouble sleeping, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, uncontrolled <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>These are not all the side effects of zolpidem tartrate tablets. Ask your doctor or pharmacist for more information.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1–800–FDA–1088.</p>
<p><span class="Bold">How should I store zolpidem tartrate tablets?</span></p>
<ul>
<li>Store at 20°-25°C (68°-77°F); excursions permitted to 15° - 30°C (59°- 86°F) [see USP Controlled Room Temperature].</li>
<li><span class="Bold">Keep zolpidem tartrate tablets and all medicines out of reach of children.</span></li>
</ul>
<p><span class="Bold">General Information about zolpidem tartrate tablets</span></p>
<ul>
<li>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.</li>
<li>Do not use zolpidem tartrate tablets for a condition for which it was not prescribed.</li>
<li>Do not share zolpidem tartrate tablets with other people, even if you think they have the same symptoms that you have. It may harm them and it is against the law.</li>
</ul>
<p>This Medication Guide summarizes the most important information about zolpidem tartrate tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about zolpidem tartrate tablets that is written for healthcare professionals. For more information about zolpidem tartrate tablets, call 1-269-544-2299.</p>
<p><span class="Bold">What are the ingredients in zolpidem tartrate tablets?</span></p>
<p><span class="Bold">Active Ingredient: </span>Zolpidem tartrate, USP</p>
<p><span class="Bold">Inactive Ingredients: </span>hypromellose, lactose monohydrate, microcrystalline cellulose, magnesium stearate, polyethylene glycol, sodium starch glycolate, titanium dioxide and ferric oxide red; the 10 mg tablet also contains ferric oxide yellow.</p>
<p><span class="Bold">Rx Only</span></p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<div class="Figure"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b87ea23e-2d54-4d10-8f10-72d4c62f3245&amp;name=zolpidem-02.jpg"></div>
<p><span class="Bold">Manufactured by:</span></p>
<p>TORRENT PHARMACEUTICALS LTD., Indrad-382 721, Dist. Mehsana, INDIA.</p>
<p><span class="Bold">For:</span></p>
<p>TORRENT PHARMA INC., 5380 Holiday Terrace, Suite 40,</p>
<p>Kalamazoo, Michigan 49009.</p>
<p>8026930                                                                                                                                                       Revised January 2011</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L12df5bef-0610-423c-a11a-5ac70be4f47f"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Relabeling and Repackaging by</span>:</p>
<p>STAT Rx USA LLC</p>
<p>Gainesville, GA  30501</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First">PACKAGE LABEL - ZOLPIDEM  C - IV   5 MG  TABLETS</p>
<br><p><img alt="Label Image 5mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b87ea23e-2d54-4d10-8f10-72d4c62f3245&amp;name=ZOLPIDEM%205MG%20LABEL%20528.jpg"></p>
<p><br></p>
<br><p><br></p>
<p><br></p>
<br><p><br></p>
<p>PACKAGE LABEL - ZOLPIDEM  C - IV   10 MG  TABLETS</p>
<br><p><img alt="Label Image 10mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b87ea23e-2d54-4d10-8f10-72d4c62f3245&amp;name=ZOLPIDEM%2010MG%20LABEL%20527.jpg"></p>
<p><br></p>
<p><br></p>
<br><p><br></p>
<p><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLPIDEM TARTRATE 		
					</strong><br><span class="contentTableReg">zolpidem tartrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-528(NDC:13668-007)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLPIDEM TARTRATE</strong> (ZOLPIDEM) </td>
<td class="formItem">ZOLPIDEM TARTRATE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">5MG</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-528-15</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-528-20</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-528-25</td>
<td class="formItem">25  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:16590-528-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:16590-528-40</td>
<td class="formItem">40  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:16590-528-56</td>
<td class="formItem">56  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:16590-528-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">8</th>
<td class="formItem">NDC:16590-528-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077903</td>
<td class="formItem">09/05/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLPIDEM TARTRATE 		
					</strong><br><span class="contentTableReg">zolpidem tartrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-527(NDC:13668-008)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLPIDEM TARTRATE</strong> (ZOLPIDEM) </td>
<td class="formItem">ZOLPIDEM TARTRATE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (Peach-Yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10MG</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-527-15</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-527-20</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-527-28</td>
<td class="formItem">28  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:16590-527-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:16590-527-45</td>
<td class="formItem">45  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:16590-527-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:16590-527-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077903</td>
<td class="formItem">09/05/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT Rx USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PSS World Medical Inc. (101822682)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT Rx USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel(16590-528, 16590-527), repack(16590-528, 16590-527)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>54b44d7d-6cd9-46bf-9eac-cce338407f4f</div>
<div>Set id: b87ea23e-2d54-4d10-8f10-72d4c62f3245</div>
<div>Version: 2</div>
<div>Effective Time: 20120913</div>
</div>
</div> <div class="DistributorName">STAT Rx USA LLC</div></p>
</body></html>
